Made by Japanese pharmaceutical firm Shionogi, ensitrelvir is approved in Japan for the treatment of mild to moderate ...

Hospital researchers say the observed increase in clinical cases of the multidrug-resistant fungus mirrors national trends.

On average over four seasons, the study found that RSV caused 84.7 hospitalizations per 100,000 among people older than 60 years, and varied significantly depending on age and certain risk factors.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies. It will mean all newborn babies in NSW can be protected against serious ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.